{
    "Clinical Trial ID": "NCT00435409",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sunitinib + Capecitabine",
        "  Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen. Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks.",
        "INTERVENTION 2: ",
        "  Capecitabine",
        "  Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks. At the time of progression, participants could have been eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily continuously."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Locally advanced or metastatic disease that can be measured. Patients with bone-only disease are also allowed to enter the study.",
        "  Previous treatment with an anthracycline and a taxane in any setting",
        "  Progression on first or second line regimen or adjuvant regimen if disease free interval less than 12 months",
        "Exclusion Criteria:",
        "  History of inflammatory carcinoma if there is no other measurable disease",
        "  More than 2 chemotherapy agents in the advanced disease setting",
        "Brain metastases"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival (PFS)",
        "  Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4.",
        "  Time frame: Baseline until disease progression (up to 3 years from first dose)",
        "Results 1: ",
        "  Arm/Group Title: Sunitinib + Capecitabine",
        "  Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen. Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks.",
        "  Overall Number of Participants Analyzed: 221",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  Independent radiology assessment: 5.5        (4.5 to 6.0)",
        "  Investigator's assessment: 5.4        (4.4 to 5.8)",
        "Results 2: ",
        "  Arm/Group Title: Capecitabine",
        "  Arm/Group Description: Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks. At the time of progression, participants could have been eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily continuously.",
        "  Overall Number of Participants Analyzed: 221",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  Independent radiology assessment: 5.9        (5.4 to 7.6)",
        "  Investigator's assessment: 5.5        (4.3 to 6.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 85/217 (39.17%)",
        "  Anaemia * 7/217 (3.23%)",
        "  Bone marrow failure * 1/217 (0.46%)",
        "  Leukopenia * 2/217 (0.92%)",
        "  Neutropenia * 3/217 (1.38%)",
        "  Thrombocytopenia * 7/217 (3.23%)",
        "  Pancytopenia * 21/217 (0.46%)",
        "  Cardiac failure acute * 1/217 (0.46%)",
        "  Congestive cardiomyopathy * 0/217 (0.00%)",
        "  Pericardial effusion * 1/217 (0.46%)",
        "  Supraventricular tachycardia * 0/217 (0.00%)",
        "Adverse Events 2:",
        "  Total: 59/215 (27.44%)",
        "  Anaemia * 1/215 (0.47%)",
        "  Bone marrow failure * 0/215 (0.00%)",
        "  Leukopenia * 0/215 (0.00%)",
        "  Neutropenia * 0/215 (0.00%)",
        "  Thrombocytopenia * 0/215 (0.00%)",
        "  Pancytopenia * 20/215 (0.00%)",
        "  Cardiac failure acute * 0/215 (0.00%)",
        "  Congestive cardiomyopathy * 1/215 (0.47%)",
        "  Pericardial effusion * 0/215 (0.00%)",
        "  Supraventricular tachycardia * 1/215 (0.47%)"
    ]
}